646066-59-3

Usage

Uses

Xli 093 is selective α5 GABAA receptor antagonist.

Upstream product

• 173990-10-8 ethyl 5-methyl-6-oxo-8-((trimethylsilyl)ethynyl)-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate 
• 173990-13-1 [3H]-RY 80 
• 78756-37-3 ethyl 8-bromo-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate 
• 3415-35-8 4-methyl-3H-1,4-benzodiazepine-2,5-(1H,4H)-dione 
• 78756-36-2 7-bromo-3,4-dihydro-4-methyl-2H-1,4-benzodiazepine-2,5-(1H)-dione 
• 646066-60-6 8-ethynyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylic acid 
• 504-63-2 trimethyleneglycol 

Relevant academic research and scientific papers

Synthesis, in Vitro Affinity, and Efficacy of a Bis 8-Ethynyl-4H-imidazo[1,5a]-[1,4]benzodiazepine Analogue, the First Bivalent α5 Subtype Selective BzR/GABAA Antagonist

The synthesis and in vitro affinity of the α5β3γ2 (α5) subtype selective BzR/GABAA antagonist 7 is described. This ligand is selective for α5 subtypes in vitro and is a potent antagonist of the effects of diazepam only at α5β3γ2 subtypes (oocytes). Ligands such as 7 will be important in the determination of which physiological function(s) are subserved by this GABAA α5 subtype.

A study of the structure-activity relationship of GABAA-benzodiazepine receptor bivalent ligands by conformational analysis with low temperature NMR and X-ray analysis

The stable conformations of GABAA-benzodiazepine receptor bivalent ligands were determined by low temperature NMR spectroscopy and confirmed by single crystal X-ray analysis. The stable conformations in solution correlated well with those in th

GABAERGIC AGENTS TO TREAT MEMORY DEFICITS

The present invention provides molecules and methods for the prevention and/or treatment of memory deficit related conditions and/or enhancement of cognizance. In a preferred embodiment, the invention includes compounds, salts and prodrugs thereof for the prevention and/or treatment of these conditions.